ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
-0,31%
S&P 500
5.308,13
0,09%
US Dollar vs BRL
5,1046
0,00%
Bitcoin
71.221,02
-0,32%
Brent Oil
82,945
-0,70%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. TSX
  6. Aeterna Zentaris Inc (AEZS)

  7. Aeterna Zentaris Inc (AEZS) Notícias

AEZS

Aeterna Zentaris (AEZS)

Aeterna Zentaris Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:TSX:AEZS
DataHoraFonteTítuloCódigoCompanhia
14/12/202310:18PR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - AEZSTSX:AEZSAeterna Zentaris Inc
14/12/202310:16PR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - AEZSTSX:AEZSAeterna Zentaris Inc
14/12/202310:14PR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - AEZSTSX:AEZSAeterna Zentaris Inc
14/12/202310:12PR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - AEZSTSX:AEZSAeterna Zentaris Inc
13/03/201908:53PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - AEZSTSX:AEZSAeterna Zentaris Inc
13/03/201908:52PR Newswire (Canada)IIROC Trade Resumption - AEZSTSX:AEZSAeterna Zentaris Inc
12/03/201916:32PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - AEZSTSX:AEZSAeterna Zentaris Inc
12/03/201916:27PR Newswire (Canada)IIROC Trading Halt - AEZSTSX:AEZSAeterna Zentaris Inc
21/12/201711:26PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - AEZS; BNETSX:AEZSAeterna Zentaris Inc
21/12/201711:23PR Newswire (Canada)IIROC Trade Resumption - AEZS; BNETSX:AEZSAeterna Zentaris Inc
03/02/201011:35PR Newswire (US)AEterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-040NASDAQ:AEZS
29/01/201011:35PR Newswire (US)AEterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of AdvancedNASDAQ:AEZS
29/01/201011:30PR Newswire (US)Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced NASDAQ:AEZS
27/01/201019:00PR Newswire (US)Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in ColorNASDAQ:AEZS
25/01/201011:35PR Newswire (US)AEterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, DouNASDAQ:AEZS
25/01/201011:30PR Newswire (US)Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-ControllNASDAQ:AEZS
22/01/201019:05PR Newswire (US)AEterna Zentaris Receives NASDAQ Notification Related to Minimum Bid PriceNASDAQ:AEZS
21/01/201011:35PR Newswire (US)AEterna Zentaris Partner, Keryx Biopharmaceuticals, to Present Poster Highlighting Clinical Activity of Perifosine (KRX-0401) atNASDAQ:AEZS
21/01/201011:30PR Newswire (US)Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 NASDAQ:AEZS
18/12/200910:15PR Newswire (US)AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and LicensinNASDAQ:AEZS
16/12/200911:35PR Newswire (US)AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients wNASDAQ:AEZS
09/12/200910:30PR Newswire (US)AEterna Zentaris Announces Appointment of New Board MemberNASDAQ:AEZS
07/12/200911:35PR Newswire (US)AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the TrNASDAQ:AEZS
07/12/200911:30PR Newswire (US)Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the TreaNASDAQ:AEZS
07/12/200910:40PR Newswire (US)AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic HyperplasiaNASDAQ:AEZS
02/12/200911:35PR Newswire (US)AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of RelapsedNASDAQ:AEZS
02/12/200911:30PR Newswire (US)Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:AEZS
24/11/200910:00PR Newswire (US)AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in EndomeNASDAQ:AEZS
11/11/200911:35PR Newswire (US)AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (NASDAQ:AEZS
11/11/200911:30PR Newswire (US)Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st AnnuaNASDAQ:AEZS
 Apresentando as notícias mais relevantes sobre:TSX:AEZS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
LUPA3
LUPATECH ON
BOV
CASH3
Meliuz S.A ON
BOV
INBR32
Inter &
BOV
GOLL4
GOL PN
BOV
LWSA3
LOCAWEB ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados